EyeCRO are Experts in preclinical efficacy studies in ophthalmic retinopathy, pharmacokinetics, both in vivo and in vitro for clinical and precise formulation services and trial batteries. EyeCRO is a preclinical ophthalmic research organization focused on studies in retina preclinical efficacy, oxygen-induced retinopathy, and ophthalmic pharmacokinetics for clinical and precise formulation services and trial batteries. EyeCRO is a preclinical ophthalmic research organization focused on studies in Laser CNV, Retina preclinical efficacy, and Ophthalmic toxicology for clinical and precise formulation services.

Web developed by Josh Bolinger website design

The Global Leader in Preclinical Ophthalmic Research

MiDROPS™

The Microemulsion Drug Ocular Penetration System (MiDROPS™) is a transformative technology for the development of eyedrop formulations.  This patented platform allows for the preparation and delivery of lipophilic agents to tissues in both the front and back of the eye.  MiDROPS™ are prepared using materials already approved by the US Food and Drug Administration for use in ophthalmic products, and by nature are intrinsically thermo-stable.

In-Vivo

EyeCRO provides numerous in-vivo research models to enable directed and meaningful preclinical drug discovery and development programs. EyeCRO also has extensive experience in various routes of administration and can customize studies depending on your needs. One of the main advantages in working with EyeCRO is our ability to be flexible.

Preserving photoreceptor cells following retinal injury: Inhibition of alternate complement pathway revealed

Retinal detachment can occur as a result of either blunt trauma or as a side effect of a variety of … Read More

Bio Matters: Family influences led EyeCRO’s executive into scientific research

Rafal Farjo, Ph.D. is chief operating officer of both EyeCRO and Charlesson, which are involved in … Read More

Pharma News: Bayer, Johns Hopkins partner to develop new ophthalmic therapies

Bayer HealthCare has entered into a five-year collaboration agreement with The Johns Hopkins … Read More

More News

Monday, August 3rd, 2015 at 10:43am
RT @Mpiresearch_cro: MPI Research welcomes James Reindel as the new Scientific Director of Pathology! http://t.co/LAPzzoj0EK http://t.co/ZU…
Monday, August 3rd, 2015 at 10:41am
Shire has agreed to buy Foresight Biotherapeutics for $300 million http://t.co/Lxnk0jefKB via @WSJ
Thursday, July 30th, 2015 at 4:08am
Preserving photoreceptor cells following retinal injury: Inhibition of alternate complement pathway revealed http://t.co/inJZy3G7le
Ophthalmic Contract Research